Rapid HLA-DQB1 genotyping for four alleles in the assessment of risk for IDDM in the Finnish population

被引:117
作者
Ilonen, J
Reijonen, H
Herva, E
Sjoroos, M
Iitia, A
Lovgren, T
Veijola, R
Knip, M
Akerblom, HK
Tuomilehto, J
Lounamaa, R
Toivanen, L
Kaprio, EA
Virtala, E
Pitkaniemi, J
Fagerlund, A
Flittner, M
Gustafsson, B
Haggqvist, C
Hakulinen, A
Herva, L
Hiltunen, P
Huhtamaki, T
Huttunen, NP
Huupponen, T
Hyttinen, M
Joki, T
Jokisalo, R
Kaar, ML
Kallio, S
Kaski, U
Laine, L
Lappalainen, J
Maenpaa, J
Makela, AL
Niemi, K
Niiranen, A
Nuuja, A
Ojajarvi, P
Otonkoski, T
Pihlajamaki, K
Pantynen, S
Rajantie, J
Sankala, J
Schumacher, J
Sillanpaa, M
Stahlberg, MR
Strahlmann, CH
Uotila, T
Varimo, P
机构
[1] UNIV TURKU, CTR IMMUNOL, FIN-20520 TURKU, FINLAND
[2] NATL PUBL HLTH INST, OULU, FINLAND
[3] UNIV TURKU, DEPT BIOTECHNOL, TURKU, FINLAND
[4] UNIV OULU, DEPT PEDIAT, SF-90100 OULU, FINLAND
[5] UNIV HELSINKI, CHILDRENS HOSP, DEPT PEDIAT 2, SF-00100 HELSINKI, FINLAND
关键词
D O I
10.2337/diacare.19.8.795
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To study the effectiveness of MHC genotyping in the assessment of risk for IDDM based on the identification of alleles that are significantly associated with risk for IDDM (DQB1*0302 and *0201) and protection from it (DQB1*0602/*0603 and *0301). RESEARCH DESIGN AND METHODS - A long series of 649 index cases of IDDM, together with their healthy siblings and 756 healthy blood donors, was collected in Finland. The samples were analyzed using a large-scale assay procedure that was developed for rapid screen ing purposes. The method utilizes time-resolved fluorometry to detect the hybridization of lanthanide-labeled allele-specific oligonucleotide probes with amplified gene product. RESULTS - A total of 61.9% of IDDM index cases had high risk (DQB1*0201/*0302) or moderate risk (DQB1*0302/x [x meaning DQB1*0302 or a nondefined allele]) genotypes compared with 14.3% of the reference population. In patients and control subjects, the frequencies of low risk genotypes were 28.0 and 22.1%, respectively, and those of decreased risk genotypes, 10.0 and 63.6%. The relative risk of a *0201/*0302 genotype was 53.5 (31.1-92.8) compared with the decreased risk genotypes (63.6% of controls). The graded risk estimation was equally efficient in assessing the risk of IDDM in siblings of child with IDDM. CONCLUSION - The near-automatic typing procedure developed is attractive for large scale screening projects, such as diabetes prevention and intervention trials.
引用
收藏
页码:795 / 800
页数:6
相关论文
共 38 条
  • [31] PARTICULAR HLA-DQ MOLECULES PLAY A DOMINANT ROLE IN DETERMINING SUSCEPTIBILITY OR RESISTANCE TO TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS
    THORSBY, E
    RONNINGEN, KS
    [J]. DIABETOLOGIA, 1993, 36 (05) : 371 - 377
  • [32] HLA-DQ-BETA GENE CONTRIBUTES TO SUSCEPTIBILITY AND RESISTANCE TO INSULIN-DEPENDENT DIABETES-MELLITUS
    TODD, JA
    BELL, JI
    MCDEVITT, HO
    [J]. NATURE, 1987, 329 (6140) : 599 - 604
  • [33] ASSESSMENT OF THE DQB1-DQA1 COMPLETE GENOTYPE ALLOWS BEST PREDICTION FOR IDDM
    TOSI, G
    PINELLI, L
    FACCHIN, A
    ACCOLLA, RS
    [J]. DIABETES CARE, 1994, 17 (09) : 1045 - 1049
  • [34] EPIDEMIOLOGY OF CHILDHOOD DIABETES-MELLITUS IN FINLAND - BACKGROUND OF A NATIONWIDE STUDY OF TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS
    TUOMILEHTO, J
    LOUNAMAA, R
    TUOMILEHTOWOLF, E
    REUNANEN, A
    VIRTALA, E
    KAPRIO, EA
    AKERBLOM, HK
    [J]. DIABETOLOGIA, 1992, 35 (01) : 70 - 76
  • [35] TUOMILEHTOWOLF E, 1993, DIABETES METAB, V19, P167
  • [36] HLA-DQB-1 CODON-57 AND GENETIC SUSCEPTIBILITY TO TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS IN FRENCH CHILDREN
    VALLETCOLOM, I
    LEVYMARCHAL, C
    ZARROUK, D
    TICHET, J
    KRISHNAMOORTHY, R
    CZERNICHOW, P
    ELION, J
    [J]. DIABETOLOGIA, 1990, 33 (03) : 174 - 176
  • [37] INSULIN AUTOANTIBODIES AND HIGH-TITER ISLET-CELL ANTIBODIES ARE PREFERENTIALLY ASSOCIATED WITH THE HLA DQA1-ASTERISK-0301-DQBU-ASTERISK-0302 HAPLOTYPE AT CLINICAL ONSET OF TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS BEFORE AGE 10 YEARS, BUT NOT AT ONSET BETWEEN AGE 10 AND 40 YEARS
    VANDEWALLE, CL
    DECRAENE, T
    SCHUIT, FC
    DELEEUW, IH
    PIPELEERS, DG
    GORUS, FK
    [J]. DIABETOLOGIA, 1993, 36 (11) : 1155 - 1162
  • [38] WEINBERG CR, 1984, DIABETOLOGIA, V26, P199